Background
Background Non-compliance Non-compliance attenuates the efficacy of treatments for attenuates the efficacy of treatments for physical and mental disorders. physical and mental disorders.
Aims Aims To assess the effectiveness of a
To assess the effectiveness of a medication managementtraining package medication managementtraining package for community mental health nurses for community mental health nurses (CMHNs) in improving compliance and (CMHNs) in improving compliance and clinical outcomes in patients with clinical outcomes in patients with schizophrenia. schizophrenia.
Method
Method Pragmatic randomised conPragmatic randomised controlled trial. Sixty CMHNs in geographical trolled trial. Sixty CMHNs in geographical clusters were assigned randomly to mediclusters were assigned randomly to medication managementtraining or treatment cation managementtraining or treatment as usual.Each CMHN identified two as usual.Each CMHN identified two patients on their case-load who were patients on their case-load who were assessed at baseline and again after 6 assessed at baseline and again after 6 months by a research worker.The primary months by a research worker.The primary efficacy outcome of interest was psychoefficacy outcome of interest was psychopathology, measured using the Positive pathology, measured using the Positive and Negative Syndrome Scale (PANSS). and Negative Syndrome Scale (PANSS).
Results

Results Nurses who had received
Nurses who had received medication managementtraining medication managementtraining produced a significantly greater reduction produced a significantly greater reduction in patients'overall psychopathology in patients'overall psychopathology compared with treatment as usual atthe compared with treatment as usual atthe end of the 6 -month study period (change end ofthe 6-month study period (change in PANSS total scores: medication in PANSS total scores: medication management management 7 716.62, treatment as usual 16.62, treatment as usual 1.17; difference 1.17; difference 7 717.79; 95% CI 17.79; 95% CI 7 724.12 to 24.12 to 7 711.45; 11.45; P P5 50.001). 0.001).
Conclusions
Conclusions Medication management Medication management training for CMHNs is effective in training for CMHNs is effective in improving clinical outcomes in patients improving clinical outcomes in patients with schizophrenia. with schizophrenia.
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Compliance with prescribed medication Compliance with prescribed medication is is observed in only around 50% of patients observed in only around 50% of patients with a range of physical and mental diswith a range of physical and mental diseases (Haynes eases (Haynes et al et al, 2002) and can be de-, 2002 ) and can be defined as the extent to which a treatment fined as the extent to which a treatment regime is followed. Poor compliance can reregime is followed. Poor compliance can reduce the efficacy of treatments, resulting in duce the efficacy of treatments, resulting in worse health outcomes for patients (World worse health outcomes for patients (World Health Organization, 2003) . A number of Health Organization, 2003) . A number of pragmatic interventions to enhance compragmatic interventions to enhance compliance have been tested in randomised pliance have been tested in randomised controlled trials. Compliance therapycontrolled trials. Compliance therapya pragmatic intervention based on moa pragmatic intervention based on motivational interviewing and cognitivetivational interviewing and cognitivebehavioural therapy -has shown some behavioural therapy -has shown some promise (Kemp & David, 1996; Kemp promise (Kemp & David, 1996; Kemp et et al al, 1998; O'Donnell , 1998; O'Donnell et al et al, 2003) but to , 2003) but to enable large numbers of clinicians to deliver enable large numbers of clinicians to deliver compliance therapy they will require traincompliance therapy they will require training. We hypothesised that training coming. We hypothesised that training community mental health nurses (CMHNs) to munity mental health nurses (CMHNs) to deliver compliance therapy would improve deliver compliance therapy would improve clinical outcomes in patients with clinical outcomes in patients with schizophrenia. schizophrenia.
METHOD METHOD
The aim of this pragmatic trial was to inThe aim of this pragmatic trial was to investigate whether medication management vestigate whether medication management training is superior to treatment as usual training is superior to treatment as usual in improving clinical outcomes for patients in improving clinical outcomes for patients with schizophrenia. The trial does not with schizophrenia. The trial does not adhere explicitly to CONSORT standards. adhere explicitly to CONSORT standards.
Community mental health nurses Community mental health nurses
We sent written invitations to CMHNs We sent written invitations to CMHNs working in two mental health care proviworking in two mental health care providers in London, inviting them to particiders in London, inviting them to participate. The CMHNs were accepted into the pate. The CMHNs were accepted into the trial if they were registered nurses and trial if they were registered nurses and had at least 12 months of post-registration had at least 12 months of post-registration experience. Once accepted into the trial experience. Once accepted into the trial each CMHN identified two patients on each CMHN identified two patients on their their case-load who satisfied the inclucase-load who satisfied the inclusion/ sion/exclusion criteria. The CMHNs were exclusion criteria. The CMHNs were aware of which group they had been aware of which group they had been allocated to when identifying appropriate allocated to when identifying appropriate patients. patients.
Patients Patients
Patients who were prescribed antipsychotic Patients who were prescribed antipsychotic medication with a recorded ICD-10 diagmedication with a recorded ICD-10 diagnosis of schizophrenia or schizoaffective nosis of schizophrenia or schizoaffective disorder (World Health Organization, disorder (World Health Organization, 1992) were invited to participate in the 1992) were invited to participate in the study if they were over 18 years of age with study if they were over 18 years of age with known or suspected poor treatment compliknown or suspected poor treatment compliance (reported by the CMHN) or who had, ance (reported by the CMHN) or who had, within the previous 12 months, at least one within the previous 12 months, at least one admission or relapse. Patients were exadmission or relapse. Patients were excluded at screening if they had a diagnosis cluded at screening if they had a diagnosis of moderate or severe learning disabilities of moderate or severe learning disabilities or organic brain disorders concurrent with or organic brain disorders concurrent with schizophrenia, were being treated by forenschizophrenia, were being treated by forensic psychiatric services (or posed a current sic psychiatric services (or posed a current or serious risk of suicide or homicide) or or serious risk of suicide or homicide) or were in-patients at the start of the trial. were in-patients at the start of the trial. Other exclusion criteria included pregnancy Other exclusion criteria included pregnancy (or a likelihood of becoming pregnant), lac-(or a likelihood of becoming pregnant), lactation and alcohol/substance dependence. tation and alcohol/substance dependence. Local ethics committees approved the study Local ethics committees approved the study and patients gave oral and written informed and patients gave oral and written informed consent to participate. consent to participate.
Study design Study design
This was a pragmatic 26-week, randomThis was a pragmatic 26-week, randomised, single-blind controlled study conised, single-blind controlled study conducted in London, UK. The CMHNs were ducted in London, UK. The CMHNs were organised into 12 clusters (five CMHNs organised into 12 clusters (five CMHNs per cluster) based on the geographical per cluster) based on the geographical location of the community mental health location of the community mental health team or general practitioner surgery where team or general practitioner surgery where they were based. The trial was staggered they were based. The trial was staggered over three phases with 20 CMHNs (four over three phases with 20 CMHNs (four clusters) in each phase. Randomisation clusters) in each phase. Randomisation sequences were prepared prior to the start sequences were prepared prior to the start of the trial and kept in opaque sealed envelof the trial and kept in opaque sealed envelopes. Clusters were randomised, at the start opes. Clusters were randomised, at the start of each of the three phases of the trial, to of each of the three phases of the trial, to receive 80 h of medication management receive 80 h of medication management training or to continue with treatment as training or to continue with treatment as usual. Patients completed a battery of usual. Patients completed a battery of self-report and research-worker-rated self-report and research-worker-rated outcome measures at baseline and again outcome measures at baseline and again after 26 weeks (Fig. 1) . The research after 26 weeks (Fig. 1) . The research workers were masked to whether the workers were masked to whether the nurse was in the training or treatment as nurse was in the training or treatment as usual group. Nurses were told not to disusual group. Nurses were told not to discuss any aspect of their training allocation cuss any aspect of their training allocation with the rater. All patients were seen either with the rater. All patients were seen either in their own home or in an out-patient in their own home or in an out-patient clinic. clinic.
Training and fidelity Training and fidelity
Medication management training consisted Medication management training consisted of 80 h of teaching delivered on a dayof 80 h of teaching delivered on a dayrelease basis over 10 weeks. Training forelease basis over 10 weeks. Training focused on teaching CMHNs the compliance cused on teaching CMHNs the compliance therapy approach detailed in a treatment therapy approach detailed in a treatment manual (Kemp manual (Kemp et al et al, 1997) . Additionally, , 1997). Additionally, the programme included training in the the programme included training in the use of a range of standardised measures to use of a range of standardised measures to assess the side-effects of medication and assess the side-effects of medication and patients' beliefs and feelings about treatpatients' beliefs and feelings about treatments, and a psychopharmacology compoments, and a psychopharmacology component that considered effective treatment nent that considered effective treatment strategies for schizophrenia and the manstrategies for schizophrenia and the management of common side-effects. A multiagement of common side-effects. A multidisciplinary team that included clinical disciplinary team that included clinical nurse specialists, psychologists and psychinurse specialists, psychologists and psychiatric pharmacists provided the training. atric pharmacists provided the training. The cost of training each CMHN was estiThe cost of training each CMHN was estimated at £1474. A detailed training manual mated at £1474. A detailed training manual is available from the authors upon request. is available from the authors upon request.
We have reported elsewhere (Gray We have reported elsewhere (Gray et al et al, , 2003 ) that training resulted in significant 2003) that training resulted in significant improvements in clinical skills. Performance improvements in clinical skills. Performance on a role-play task was rated independently on a role-play task was rated independently using the Cognitive Therapy Scale (CTS; using the Cognitive Therapy Scale (CTS; Vallis Vallis et al et al, 1986) both pre-and post-, 1986) both pre-and posttraining. A score of 30 indicates satisfactory training. A score of 30 indicates satisfactory clinical skills. The mean pre-training score clinical skills. The mean pre-training score was 13.9. Following training CTS total was 13.9. Following training CTS total scores improved significantly (mean 30.6, scores improved significantly (mean 30.6, P P5 50.01). Nurses who attended training 0.01). Nurses who attended training also reported a high degree of satisfaction also reported a high degree of satisfaction and clinical applicability. and clinical applicability.
Outcome measures Outcome measures
All patient interviews were performed by All patient interviews were performed by one of two research workers (R.G. and Sara one of two research workers (R.G. and Sara Dickson, see Acknowledgements) masked Dickson, see Acknowledgements) masked to the training condition. Both researchers to the training condition. Both researchers attended a 1-day training workshop in attended a 1-day training workshop in administering and reliably rating the administering and reliably rating the Positive and Negative Syndrome Scale Positive and Negative Syndrome Scale (PANSS; Kay (PANSS; Kay et al et al, 1989) and obtained a , 1989) and obtained a satisfactory level of interrater reliability. satisfactory level of interrater reliability.
Primary outcome measure Primary outcome measure
Positive and Negative Syndrome Scale Positive and Negative Syndrome Scale
The PANSS is a widely used measure for The PANSS is a widely used measure for evaluating the symptoms of schizophrenia evaluating the symptoms of schizophrenia in clinical trials of both pharmacological in clinical trials of both pharmacological and psychological interventions. Thirty and psychological interventions. Thirty items are rated on a seven-point scale items are rated on a seven-point scale following the general format of the Brief following the general format of the Brief Psychiatric Rating Scale (Overall & Gorham, Psychiatric Rating Scale (Overall & Gorham, 1962) . The PANSS has strict operational 1962). The PANSS has strict operational criteria for conducting a 30-40 min patient criteria for conducting a 30-40 min patient interview, thorough definitions for all 30 interview, thorough definitions for all 30 items and detailed rating criteria for each items and detailed rating criteria for each level of psychopathology (Kay level of psychopathology (Kay et al et al, , 1989) . The measure has established inter-1989). The measure has established interrater, test-retest and internal reliability, rater, test-retest and internal reliability, and internal, external and construct validity and internal, external and construct validity (Kay (Kay et al et al, 1989) . A ten-point reduction in , 1989). A ten-point reduction in PANSS total scores would represent a PANSS total scores would represent a clinically important training effect. clinically important training effect.
Secondary outcome measures Secondary outcome measures
Three further scales were used to assess efThree further scales were used to assess efficacy; the Hogan Drug Attitude Inventory ficacy; the Hogan Drug Attitude Inventory (DAI-30; Hogan (DAI-30; Hogan et al et al, 1983) , the Clinician , 1983), the Clinician Rating of Compliance Scale (Kemp Rating of Compliance Scale (Kemp et al et al, , 1998 ) and the Liverpool University Neuro-1998) and the Liverpool University Neuroleptic Side Effect Rating Scale (LUNSERS; leptic Side Effect Rating Scale (LUNSERS; Day Day et al et al, 1995) . The DAI-30 is a 30-item , 1995). The DAI-30 is a 30-item self-report measure predictive of compliself-report measure predictive of compliance in people with schizophrenia. Each ance in people with schizophrenia. Each item is rated by the patient as being true item is rated by the patient as being true or false and produces a total score ranging or false and produces a total score ranging from +30 to from +30 to 7 730. A positive score is 30. A positive score is predictive of compliance and a negative predictive of compliance and a negative score is predictive of non-compliance. The score is predictive of non-compliance. The Clinician Rating of Compliance Scale is Clinician Rating of Compliance Scale is an observer rating of compliance on a an observer rating of compliance on a seven-point scale ranging from 1 (complete seven-point scale ranging from 1 (complete refusal) to 7 (active participation in treatrefusal) to 7 (active participation in treatment). The LUNSERS is a self-report ment). The LUNSERS is a self-report measure of the side-effects of antipsychotic measure of the side-effects of antipsychotic medication. Forty-one items cover psychomedication. Forty-one items cover psychological, neurological, autonomic, hormonal logical, neurological, autonomic, hormonal and miscellaneous side-effects. Each item is and miscellaneous side-effects. Each item is rated on a five-point scale ranging from rated on a five-point scale ranging from 'not at all' to 'very much', based on how 'not at all' to 'very much', based on how frequently the patient has experienced the frequently the patient has experienced the side-effect in the preceding month. side-effect in the preceding month.
Additional patient information Additional patient information
Patients' age, gender, ethnicity, diagnosis Patients' age, gender, ethnicity, diagnosis and duration of illness were collected from and duration of illness were collected from the patients' medical notes at the baseline the patients' medical notes at the baseline assessment and confirmed with the patient assessment and confirmed with the patient at interview. All the medication that at interview. All the medication that patients were prescribed on the day of patients were prescribed on the day of assessment was recorded. The dose of assessment was recorded. The dose of antipsychotic medication was converted to antipsychotic medication was converted to chlorpromazine equivalents using the chlorpromazine equivalents using the World Health Organization's Anatomical World Health Organization's Anatomical Therapeutic Chemical Classification (World Therapeutic Chemical Classification (World Health Organization, 1993) . We also Health Organization, 1993). We also observed for any serious or unexpected observed for any serious or unexpected adverse events throughout the trial, including adverse events throughout the trial, including death or attempted suicide. death or attempted suicide.
Nurse information Nurse information
Nurses completed a brief questionnaire Nurses completed a brief questionnaire detailing their age, gender, ethnicity, clinidetailing their age, gender, ethnicity, clinical and academic experience, grade and cal and academic experience, grade and case-load. case-load.
Statistical analyses Statistical analyses
A sample size of 120 patients (and therefore A sample size of 120 patients (and therefore 60 CMHNs) was chosen to determine the 60 CMHNs) was chosen to determine the effect of medication management training effect of medication management training on the clinical outcome of patients with on the clinical outcome of patients with schizophrenia. Power calculations sugschizophrenia. Power calculations suggested that to detect a ten-point difference gested that to detect a ten-point difference in PANSS total scores, assuming a standard in PANSS total scores, assuming a standard deviation of 12.4 , 120 deviation of 12.4 , 120 patients should be recruited to give an patients should be recruited to give an 80% power at a significance level of 5%, 80% power at a significance level of 5%, allowing for drop-out of 20%. Our power allowing for drop-out of 20%. Our power analysis did not allow for clustering of analysis did not allow for clustering of patients. Retrospectively it would have patients. Retrospectively it would have been preferable in principle to have allowed been preferable in principle to have allowed for this through the variance inflation for this through the variance inflation factor. In fact, the observed intraclass factor. In fact, the observed intraclass correlation within clusters was very low correlation within clusters was very low and therefore any underestimate of power and therefore any underestimate of power would have been negligible. would have been negligible. Data were analysed initially using the Data were analysed initially using the Statistical Package for the Social Sciences Statistical Package for the Social Sciences Version 11 for Windows to compare the Version 11 for Windows to compare the randomised groups of nurses and patients randomised groups of nurses and patients at baseline. The distributions of the outat baseline. The distributions of the outcome variables were approximately normal come variables were approximately normal at baseline. Differences between the two at baseline. Differences between the two groups at baseline and after intervention groups at baseline and after intervention are reported with confidence intervals (but are reported with confidence intervals (but not the estimate of the intervention effect) not the estimate of the intervention effect) adjusted for the effect of clustering. This adjusted for the effect of clustering. This is achieved by applying the variance inflais achieved by applying the variance inflation factor based on the intraclass correlation factor based on the intraclass correlation to the within-group standard errors tion to the within-group standard errors . This also allows . This also allows a simple adjustment to the standard a simple adjustment to the standard t t-test -test and is implemented in the and is implemented in the clttest clttest routine routine in Stata version 7 for Windows. The in Stata version 7 for Windows. The effects of the intervention are reported as effects of the intervention are reported as change scores. Sensitivity checks were change scores. Sensitivity checks were performed on all significant findings by perperformed on all significant findings by performing a mixed effect regression (using the forming a mixed effect regression (using the xtreg-mle xtreg-mle procedure), controlling for baseprocedure), controlling for baseline level, age, gender and ethnic group line level, age, gender and ethnic group and allowing for clustering at geographical and allowing for clustering at geographical and CMHN cluster level separately. and CMHN cluster level separately.
RESULTS RESULTS
Sample of CMHNs Sample of CMHNs
Sixty CMHNs were recruited in the trial Sixty CMHNs were recruited in the trial and randomised (Fig. 1) . Prior to recruiting and randomised (Fig. 1 ). Prior to recruiting the patients, eight CMHNs withdrew from the patients, eight CMHNs withdrew from the trial. Five had found alternative the trial. Five had found alternative employment and two withdrew consent, employment and two withdrew consent, reporting that they were too busy to attend reporting that they were too busy to attend the training. One withdrew for an unspecithe training. One withdrew for an unspecified reason. The demographic profile of fied reason. The demographic profile of CMHNs who entered the trial (Table 1) CMHNs who entered the trial (Table 1 ) was similar to that described in the national was similar to that described in the national census , although census , although CMHNs in this study were from more CMHNs in this study were from more diverse ethnic backgrounds. The only basediverse ethnic backgrounds. The only baseline difference between the two groups was line difference between the two groups was that nurses in the experimental group were that nurses in the experimental group were more experienced. more experienced.
Sample of patients Sample of patients
The CMHNs identified 89 patients to take The CMHNs identified 89 patients to take part in the study (Fig. 1) . At trial entry, separt in the study (Fig. 1) . At trial entry, seven were excluded because they did not ven were excluded because they did not satisfy the inclusion/exclusion criteria: five satisfy the inclusion/exclusion criteria: five were not diagnosed with schizophrenia or were not diagnosed with schizophrenia or schizoaffective disorder and two were not schizoaffective disorder and two were not on the case-load of the CMHN who reon the case-load of the CMHN who referred them. Of the 82 who were eligible ferred them. Of the 82 who were eligible to take part, three refused to participate, to take part, three refused to participate, two withdrew their consent and five did two withdrew their consent and five did not complete the baseline assessment. not complete the baseline assessment. Seventy-two patients gave written consent Seventy-two patients gave written consent and entered the study, which is a mean of and entered the study, which is a mean of 1.4 per CMHN. The patients who entered 1.4 per CMHN. The patients who entered the trial (Table 2) were similar to populathe trial (Table 2) were similar to populations of patients with schizophrenia in tions of patients with schizophrenia in other trials of compliance interventions other trials of compliance interventions (Kemp (Kemp et al et al, 1998) . The two groups were , 1998). The two groups were comparable in terms of demographic feacomparable in terms of demographic features, duration of illness, age at illness and tures, duration of illness, age at illness and number of admissions. number of admissions.
Follow-up assessment Follow-up assessment
All CMHNs who entered the trial comAll CMHNs who entered the trial completed training (i.e. attended pleted training (i.e. attended 4 480% of the 80% of the course). Of the 72 patients who entered course). Of the 72 patients who entered the trial 53 (74%; 29 in the training group the trial 53 (74%; 29 in the training group and 24 in the treatment-as-usual groups; and 24 in the treatment-as-usual groups; Fig. 1) were assessed on the primary Fig. 1) were assessed on the primary outcome measure (PANSS total) at the trial outcome measure (PANSS total) at the trial end-point. Eleven refused to be interviewed end-point. Eleven refused to be interviewed but did not withdraw consent, five were not but did not withdraw consent, five were not available for interview, two had moved available for interview, two had moved away and one could not be traced. There away and one could not be traced. There was no evidence for differential drop-out. was no evidence for differential drop-out. For those who were missing at follow-up, For those who were missing at follow-up, the PANSS total baseline score was similar the PANSS total baseline score was similar in both groups (training in both groups (training¼68.5 68.5 v v. treatment . treatment as usual as usual¼67.7). 67.7).
Medication dosage Medication dosage
The dose of antipsychotic medication The dose of antipsychotic medication prescribed for the duration of the trial prescribed for the duration of the trial was stable in both groups. At baseline there was stable in both groups. At baseline there was no significant difference between the was no significant difference between the two groups in the mean dose of antitwo groups in the mean dose of antipsychotic medication (in chlorpromazine psychotic medication (in chlorpromazine equivalents) prescribed (training equivalents) prescribed (training¼400 mg/ 400 mg/ day day v v. treatment as usual . treatment as usual¼469 mg/day). 469 mg/day). There was also no evidence for a difference There was also no evidence for a difference in the proportion of patients prescribed in the proportion of patients prescribed atypical antipsychotics (training atypical antipsychotics (training n n¼6 6 v v. . treatment as usual treatment as usual n n¼8). At the trial 8). At the trial end-point there had been no significant end-point there had been no significant changes between the groups in the dose of changes between the groups in the dose of antipsychotic medication prescribed (trainantipsychotic medication prescribed (training ing¼307 mg/day 307 mg/day v v. treatment as usual . treatment as usual ¼379 mg/day) or the proportion prescribed 379 mg/day) or the proportion prescribed atypicals (training atypicals (training n n¼3 3 v v. treatment as . treatment as usual usual n n¼6). 6).
Efficacy outcomes Efficacy outcomes
Baseline scores (Table 2) were indicative of Baseline scores (Table 2) were indicative of moderate levels of schizophrenic symptoms, moderate levels of schizophrenic symptoms, and ambivalence about the need for takingand ambivalence about the need for takingmedication. The LUNSERS scores suggested medication. The LUNSERS scores suggested that patients were experiencing a moderate that patients were experiencing a moderate number of side-effects from antipsychotic number of side-effects from antipsychotic medication. Although patients in the intermedication. Although patients in the intervention group tended to have more sympvention group tended to have more symptoms, lower compliance and more sidetoms, lower compliance and more sideeffects than those in the treatment-as-usual effects than those in the treatment-as-usual group, the differences were not statistically group, the differences were not statistically significant. significant. Statistically significant improvements Statistically significant improvements were seen in the medication management were seen in the medication management training group compared with the training group compared with the treatment-as-usual group (Table 3) in treatment-as-usual group (Table 3) in overall psychopathology (PANSS total), overall psychopathology (PANSS total), attitudes towards antipsychotic medication attitudes towards antipsychotic medication (DAI-30) and compliance. No significant (DAI-30) and compliance. No significant differences between the groups were seen in differences between the groups were seen in patients' antipsychotic side-effects. The senpatients' antipsychotic side-effects. The sensitivity analyses adjusting for both cluster sitivity analyses adjusting for both cluster effects and confounders showed very simieffects and confounders showed very similar results, with a slight attenuation of the lar results, with a slight attenuation of the effect for the PANSS total score (mean effect for the PANSS total score (mean difference difference¼16.1). Clinically significant 16.1). Clinically significant improvements in psychopathology (defined improvements in psychopathology (defined as an improvement of at least 30%) were as an improvement of at least 30%) were seen in 6 of the 29 patients in the mediseen in 6 of the 29 patients in the medication management group but in none of cation management group but in none of the 24 in the treatment-as-usual group. the 24 in the treatment-as-usual group.
Safety assessments Safety assessments
Relapse was defined as a 30% or more Relapse was defined as a 30% or more increase in PANSS total scores. None of increase in PANSS total scores. None of the patients in the training group and the patients in the training group and one in the treatment-as-usual group one in the treatment-as-usual group experienced a relapse during the trial. experienced a relapse during the trial. There were no patient deaths during the There were no patient deaths during the trial and no attempted suicides. trial and no attempted suicides.
DISCUSSION DISCUSSION
The aim of this trial was to assess the effecThe aim of this trial was to assess the effectiveness of medication management traintiveness of medication management training compared with treatment as usual in ing compared with treatment as usual in improving clinical outcomes for patients improving clinical outcomes for patients with schizophrenia. with schizophrenia.
Community mental health nurses Community mental health nurses
The CMHNs provide much of the day-toThe CMHNs provide much of the day-today care for people with schizophrenia day care for people with schizophrenia and they are ideally placed to deliver comand they are ideally placed to deliver compliance therapy. In this trial the demopliance therapy. In this trial the demographic characteristics of CMHNs were graphic characteristics of CMHNs were comparable with those in the national comparable with those in the national census, suggesting that they were represencensus, suggesting that they were representative of those currently practising in the tative of those currently practising in the UK. The only important difference was that UK. The only important difference was that CMHNs were from a more diverse ethnic CMHNs were from a more diverse ethnic background. However, this would be background. However, this would be anticipated, given that the study was anticipated, given that the study was carried out in south London where the carried out in south London where the population is more ethnically diverse. The population is more ethnically diverse. The training and treatment-as-usual groups training and treatment-as-usual groups were generally well matched. were generally well matched.
Patient population Patient population
People with schizophrenia are often nonPeople with schizophrenia are often noncompliant with antipsychotic medication, compliant with antipsychotic medication, resulting in increased levels of psychoresulting in increased levels of psychopathology or relapse. The baseline demopathology or relapse. The baseline demographic and clinical data from this study graphic and clinical data from this study underscore this observation. In an apparunderscore this observation. In an apparently stable population prescribed fairly ently stable population prescribed fairly 1 6 0 1 6 0 et al, 1998) and suggest that , 1998) and suggest that medication management training equips medication management training equips CMHNs with the skills that they need to CMHNs with the skills that they need to be effective in delivering compliance therbe effective in delivering compliance therapy. However, anticipated improvements apy. However, anticipated improvements in antipsychotic side-effects were not reain antipsychotic side-effects were not realised. Medication management training lised. Medication management training was acceptable to patients and did not was acceptable to patients and did not result in any unexpected findings with result in any unexpected findings with regard to safety. regard to safety.
Methodological considerations Methodological considerations
The proportion of patients for whom comThe proportion of patients for whom complete data were not available was high plete data were not available was high (26%) but below the average rate of 33% (26%) but below the average rate of 33% reported in a systematic review of dropreported in a systematic review of dropout in published randomised trials with this out in published randomised trials with this patient population (Wahlbeck patient population (Wahlbeck et al et al, 2001) . , 2001). The large number of patients dropping The large number of patients dropping out of the trial may be explained by the natout of the trial may be explained by the nature of the disorder: patients are chaotic, ure of the disorder: patients are chaotic, they miss appointments and are often disthey miss appointments and are often distrustful of strangers. The study may have trustful of strangers. The study may have benefitted from a comparison with an inert benefitted from a comparison with an inert training intervention that would allow for training intervention that would allow for training time to be controlled. However, it training time to be controlled. However, it would be unethical and expensive to prowould be unethical and expensive to provide training that was of no real benefit to vide training that was of no real benefit to CMHNs. In this study we used self-report CMHNs. In this study we used self-report (DAI-30) and clinician ratings of compli-(DAI-30) and clinician ratings of compliance. These measures have been criticised ance. These measures have been criticised because they may introduce observer bias. because they may introduce observer bias. However, direct methods such as electronic However, direct methods such as electronic monitoring were impractical and costly monitoring were impractical and costly and, in any case, also can be subject to bias. and, in any case, also can be subject to bias. Patients were followed up for a relatively Patients were followed up for a relatively short (6-month) period. It would be importshort (6-month) period. It would be important to examine whether the improvements ant to examine whether the improvements observed are maintained over a longer observed are maintained over a longer period of time or whether the effects of period of time or whether the effects of training begin to degrade. Allowing training begin to degrade. Allowing CMHNs to identify patients for inclusion CMHNs to identify patients for inclusion in the trial after randomisation may have in the trial after randomisation may have introduced the potential for selection bias. introduced the potential for selection bias. This is suggested by the baseline differThis is suggested by the baseline differences, even though they are non-significant. ences, even though they are non-significant. Recruiting patients who satisfied the Recruiting patients who satisfied the inclusion/exclusion criteria randomly from inclusion/exclusion criteria randomly from CMHNs case-loads could have addressed CMHNs case-loads could have addressed this. this. O'Donnell, C., Donohoe, G., Sharkey, L., O'Donnell, C., Donohoe, G., Sharkey, L., et al et al (2003 Sharkey, L., et al et al ( ) (2003 
